GlassScriptPhysician profile
Kyle F Medlin
NPI 1336532746
$3,630.40
in general payments reported to CMS, 2019-2025
53 companies · $1,143 in 2025
The $1,143 reported for 2025 was more than what 87% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $646 · 2022: $616 · 2023: $583 · 2024: $642 · 2025: $1,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,367.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $505.54 | 2023-2025 | |
| Abbvie INC. | $382.50 | 2021-2025 | |
| Janssen Biotech, INC. | $278.52 | 2021-2025 | Balversa, Erleada, Akeega |
| Daiichi Sankyo INC. | $228.41 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Glaxosmithkline, LLC. | $181.79 | 2021-2025 | Zejula, Jemperli |
| Merck Sharp & Dohme LLC | $162.88 | 2022-2025 | Keytruda, Keytruda Qlex, Welireg |
| Pharmacyclics LLC, An Abbvie Company | $157.01 | 2021-2023 | Epkinly, Imbruvica |
| Amgen INC. | $134.55 | 2021-2023 | Lumakras |
| Eisai INC. | $129.15 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $120.28 | 2021-2025 | Enhertu, Imfinzi |
| Genzyme Corporation | $69.48 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.76 | 2021-2025 | Fruzaqla, Iclusig |
| Exelixis INC. | $65.38 | 2021-2025 | Cabometyx |
| Pfizer INC. | $65.06 | 2024-2025 | |
| Incyte Corporation | $62.28 | 2024-2025 | Monjuvi, Jakafi |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Medlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.